Position in RNA
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,681,250
New position
Shares Held
125,000
first reported quarter
Ownership
0.731%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#31
of 153 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Anson Funds Management LP holds $75,470,163 across 8 Biotechnology names. RNA ranks #4 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLS |
SELLAS Life Sciences Group, Inc.
|
4,500,000 | $66,420,000 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
20,000 | $3,745,600 | |
| 3 | NKTR |
Nektar Therapeutics
|
40,535 | $2,829,748 | |
| 4 | RNA |
Atrium Therapeutics, Inc.
This page
|
125,000 | $1,681,250 | |
| 5 | CAPR |
Capricor Therapeutics, Inc.
|
25,000 | $602,000 | |
| 6 | CELZ |
Creative Medical Technology Holdings, Inc.
|
105,549 | $153,046 | |
| 7 | OABI |
OmniAb, Inc.
|
11,833 | $29,109 | |
| 8 | YARW |
Yarrow Bioscience, Inc.
|
14,455 | $9,410 |
All Filings in RNA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,681,250 | 125,000 | Shares | Defined | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||